Suppression of glycogen synthase kinase 3 activity reduces tumor growth of prostate cancer in vivo

Prostate

Volumn 71, Issue 8, 2011, Pages 835-845

  Zhu, Qing ^a,b   Yang, Jun ^b,c   Han, Suxia ^a   Liu, Jihong ^c   Holzbeierlein, Jeffery ^b   Thrasher, J Brantley ^b   Li, Benyi ^a,b  

^a XI'AN JIAOTONG UNIVERSITY   (China)

^b UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^c HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

C EBP ; GSK 3; Prostate cancer; TRAMP; Tumor growth; Xenograft

Indexed keywords

ADENOSINE TRIPHOSPHATE; BROXURIDINE; CCAAT ENHANCER BINDING PROTEIN ALPHA; CELL DNA; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; LITHIUM CHLORIDE; LUCIFERASE; MONOCLONAL ANTIBODY KI 67; SMALL INTERFERING RNA; THIADIAZOLE DERIVATIVE; THIADIAZOLIDINONE 8; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER INHIBITION; CARCINOGENESIS; CELL PROLIFERATION; CONTROLLED STUDY; DNA SYNTHESIS; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROSTATE CANCER; TRANSACTIVATION; TRANSGENIC MOUSE; TUMOR GROWTH; TUMOR VOLUME; XENOGRAFT;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS; CCAAT-ENHANCER-BINDING PROTEIN-ALPHA; CELL LINE, TUMOR; CELL PROLIFERATION; GLYCOGEN SYNTHASE KINASE 3; HUMANS; LITHIUM CHLORIDE; MALE; MICE; MICE, INBRED C57BL; MICE, NUDE; MICE, TRANSGENIC; OLIGOPEPTIDES; PROSTATIC NEOPLASMS; RNA, SMALL INTERFERING; THIADIAZOLES;

EID: 79953715165     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21300     Document Type: Article

References (46)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-249.
2. Huggins C, Hodges CV. Studies on prostatic cancer: The effects of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941;1:293-297.
3. Mohla S, Stearns V, Sathyamoorthy N, Rosenfeld MG, Nelson P. The biology of hormone refractory breast and prostate cancer: An NCI workshop report. Cancer Biol Ther 2009;8:1975-1985.
4. Harris WP, Mostaghel EA, Nelson PS, Montgomery B. Androgen deprivation therapy: Progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin Pract Urol 2009;6:76-85.
5. Thompson IM, Tangen CM, Goodman PJ, Lucia MS, Klein EA. Chemoprevention of prostate cancer. J Urol 2009;182:499-507.
6. Schröder FH, van Weerden WM. Prostate cancer - Chemo-prevention. Eur J Cancer 2009;45 (Suppl 1):355-359.
7. Forde JE, Dale TC. Glycogen synthase kinase 3: A key regulator of cellular fate. Cell Mol Life Sci 2007;64:1930-1944. (Pubitemid 47094432)
8. Kim N-G, Xu C, Gumbiner BM. Identification of targets of the Wnt pathway destruction complex in addition to β-catenin. Proc Natl Acad Sci USA 2009;106:5165-5170.
9. Force T, Woodgett JR. Unique and overlapping functions of GSK-3 isoforms in cell differentiation and proliferation and cardiovascular development. J Biol Chem 2009;284:9643-9647.
10. Luo J. Glycogen synthase kinase 3beta (GSK3beta) in tumorigenesis and cancer chemotherapy. Cancer Lett 2009;273:194-200.
11. Lee TT, Ho YS, Yu JS, Yang SD. Overexpression of cellular activity and protein level of protein kinase FA/GSK-3 alpha correlates with human thyroid tumor cell dedifferentiation. J Cell Biochem 1995;58:474-480.
12. Yang SD, Yu JS, Yang CC, Lee SC, Lee TT, Ni MH, Kuan CY, Chen HC. Overexpression of protein kinaseFA/GSK-3 alpha (a proline-directed protein kinase) correlates with human hepatoma dedifferentiation/progression. J Cell Biochem 1996;61:238-245.
13. Hsueh SF, Lai MT, Yang CC, Chung YC, Hsu CP, Peng CC, Fu HH, Cheng YM, Chang KJ, Yang SD. Association of over-expressed proline-directed protein kinase F(A) with chemoresistance, invasion, and recurrence in patients with bladder carcinoma. Cancer 2002;95:775-783.
14. Lau KF, Miller CC, Anderton BH, Shaw PC. Expression analysis of glycogen synthase kinase-3 in human tissues. J Pept Res 1999;54:85-91. (Pubitemid 29334091)
15. Yang C-C, Hsu C-P, Sheu J-C, Mai X-Y, Yang S-D. Differential tyrosinephosphorylation/activation of oncogenic proline-directed protein kinase F (A)/GSK-3alpha in well and poorly differentiated human prostate carcinoma cells. J Protein Chem 1998;17:329-335. (Pubitemid 28242303)
16. Li R, Erdamar S, Dai H, Sayeeduddin M, Frolov A, Wheeler TM, Ayala GE. Cytoplasmic accumulation of glycogen synthase kinase-3β is associated with aggressive clinicopathological features in human prostate cancer. Anticancer Res 2009;29:2077-2081.
17. Liao X, Thrasher JB, Holzbeierlein J, Stanley S, Li B. Glycogen synthase kinase-3beta activity is required for androgen-stimulated gene expression in prostate cancer. Endocrinology 2004;145:2941-2949. (Pubitemid 38686243)
18. Sun A, Shanmugam I, Song J, Terranova PF, Thrasher JB, Li B. Lithium suppresses cell proliferation by interrupting E2F-DNA interaction and subsequently reducing S-phase gene expression in prostate cancer. Prostate 2007;67:976-988. (Pubitemid 46828931)
19. Mazor M, Kawano Y, Zhu H, Waxman J, Kypta RM. Inhibition of glycogen synthase kinase-3 represses androgen receptor activity and prostate cancer cell growth. Oncogene 2004;23:7882-7892. (Pubitemid 39457038)
20. Rinnab L, Schütz SV, Diesch J, Schmid E, Küfer R, Hautmann RE, Spindler KD, Cronauer MV. Inhibition of glycogensynthase kinase-3 in androgen-responsive prostate cancer celllines: Are GSK inhibitors therapeutically useful? Neoplasia 2008;10:624-634.
21. Cohen P, Goedert M. GSK3 inhibitors: Development and therapeutic potential. Nat Rev Drug Discov 2004;3:479-487. (Pubitemid 38807530)
22. Klein PS, Melton DA. A molecular mechanism for the effect of lithium on development. Proc Natl Acad Sci USA 1996;93:8455-8459. (Pubitemid 26269579)
23. Stambolic V, Ruel L, Woodgett JR. Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signaling in intact cells. Curr Biol 1996;6:1664-1668. (Pubitemid 27050234)
24. Cohen Y, Chetrit A, Cohen Y, Sirota P, Modan B. Cancer morbidity in psychiatric patients: Influence of lithium carbonate treatment. Med Oncol 1998;15:32-36. (Pubitemid 28248297)
25. Ballin A, Aladjem M, Banyash M, Boichis H, Barzilay Z, Gal R, Witz IP. The effect of lithium chloride on tumour appearance and survival of melanomabearing mice. Br J Cancer 1983;48:83-87. (Pubitemid 13067949)
26. Ziche M, Maiorana A, Oka T, Gullino PM. Influence of lithium on mammary tumor growth in vivo. Cancer Lett 1980;9:219-224. (Pubitemid 10070961)
27. Martinez A, Alonso M, Castro A, Pérez C, Moreno FJ. First non-ATP competitive glycogen synthase kinase 3 beta (GSK-3beta) inhibitors: Thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease. J Med Chem 2002;45:1292-1299. (Pubitemid 34263565)
28. Plotkin B, Kaidanovich O, Talior I, Eldar-Finkelman H. Insulin mimetic action of synthetic phosphorylated peptide inhibitors of glycogen synthase kinase-3. J Pharmacol Exp Ther 2003;305:974-980. (Pubitemid 36621426)
29. Kaidanovich-Beilin O, Eldar-Finkelman H. Long-term treatment with novel glycogen synthase kinase-3 inhibitor improves glucose homeostasis in ob/ob mice: Molecular characterization in liver and muscle. J Pharmacol Exp Ther 2006;316:17-24. (Pubitemid 41832576)
30. Li B, Sun A, Youn H, Hong Y, Terranova PF, Thrasher JB, Xu P, Spencer D. Conditional Akt activation promotes androgenin-dependent progression of prostate cancer. Carcinogenesis 2007;28:572-583. (Pubitemid 46523353)
31. Ghosh PK, Biswas NM, Ghosh D. Effect of lithium chloride on spermatogenesis and testicular steroidogenesis in mature albino rats: Duration dependent response. Life Sci 1991;48:649-657.
32. Noble W, Planel E, Zehr C, Olm V, Meyerson J, Suleman F, Gaynor K, Wang L, LaFrancois J, Feinstein B, Burns M, Krishnamurthy P, Wen Y, Bhat R, Lewis J, Dickson D, Duff K. Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc Natl Acad Sci USA 2005;102:6990-6995. (Pubitemid 40675429)
33. Moore CM, Demopulos CM, Henry ME, Steingard RJ, Zamvil L, Katic A, Breeze JL, Moore JC, Cohen BM, Renshaw PF. Brain-toserum lithium ratio and age: An in vivo magnetic resonance spectroscopy study. Am J Psychiatry 2002;159:1240-1242. (Pubitemid 34743271)
34. Greenberg NM, DeMayo F, Finegold MJ, Medina D, Tilley WD, Aspinall JO, Cunha GR, Donjacour AA, Matusik RJ, Rosen JM. Prostate cancer in a transgenic mouse. Proc Natl Acad Sci USA 1995;92:3439-3443.
35. Kaplan-Lefko PJ, Chen TM, Ittmann MM, Barrios RJ, Ayala GE, Huss WJ, Maddison LA, Foster BA, Greenberg NM. Pathobiology ofautochthonous prostate cancer in a pre-clinical transgenicmouse model. Prostate 2003;55:219-237. (Pubitemid 36532401)
36. Johnson PF. Molecular stop signs: Regulation of cell-cycle arrest by C/EBP transcription factors. J Cell Sci 2005;118:2545-2555. (Pubitemid 40932881)
37. Liu HK, Perrier S, Lipina C, Finlay D, McLauchlan H, Hastie CJ, Hundal HS, Sutherland C. Functional characterisation of the regulation of CAAT enhancer binding protein alpha by GSK-3 phosphorylation of Threonines 222/226. BMC Mol Biol 2006;7:14.
38. Ross SE, Erickson RL, Hemati N, MacDougald OA. Glycogen synthase kinase 3 is an insulin-regulated C/EBPα kinase. Mol Cell Biol 1999;19:8433-8441. (Pubitemid 30414037)
39. Mai W, Kawakami K, Shakoori A, Kyo S, Miyashita K, Yokoi K, Jin M, Shimasaki T, Motoo Y, Minamoto T. Deregulated GSK3β sustains gastrointestinal cancer cells survival by modulating human telomerase reverse transcriptase and telomerase. Clin Cancer Res 2009;15:6810-6819.
40. Miyashita K, Kawakami K, Nakada M, Mai W, Shakoori A, Fujisawa H, Hayashi Y, Hamada J, Minamoto T. Potential therapeutic effect of glycogen synthase kinase 3beta inhibition against human glioblastoma. Clin Cancer Res 2009;15:887-897.
41. Koschmieder S, Halmos B, Levantini E, Tenen DG. Dysregulation of the C/EBPα differentiation pathway in human cancer. J Clin Oncol 2009;27:619-628.
42. Chattopadhyay S, Gong EY, Hwang M, Park E, Lee HJ, Hong CY, Choi HS, Cheong JH, Kwon HB, Lee K. The CCAAT enhancer-binding protein-alpha negatively regulates the transactivation of androgen receptor in prostate cancer cells. Mol Endocrinol 2006;20:984-995.
43. Yin H, Radomska HS, Tenen DG, Glass J. Down regulation of PSA by C/EBPα is associated with loss of AR expression and inhibition of PSA promoter activity in the LNCaP cell Line. BMC Cancer 2006;6:158.
44. Zhang J, Gonit M, Salazar MD, Shatnawi A, Shemshedini L, Trumbly R, Ratnam M. C/EBPα redirects androgen receptor signaling through a unique bimodal interaction. Oncogene 2010;29:723-738.
45. Shim M, Smart RC. Lithium stabilizes the CCAAT/enhancer-binding protein α (C/EBPα) through a glycogen synthase kinase 3 (GSK3)-independent pathway involving direct inhibition of proteasomal activity. J Biol Chem 2003;278:19674-19681. (Pubitemid 36799152)
46. Ougolkov AV, Billadeau DD. Targeting GSK-3: A promising approach for cancer therapy? Future Oncol 2006;2:91-100.